Morpho Detection, part of Morpho, Safran group’s security business, has entered into a definitive agreement to acquire Syagen Technology, of Tustin, California. Syagen is a mass spectrometry technology development company for security applications.
Morpho Detection, part of Morpho, Safran group's security business, has entered into a definitive agreement to acquire Syagen Technology, of Tustin, California. Syagen is a mass spectrometry technology development company for security applications.
The acquisition of Syagen strengthens Morpho's position as the provider of explosives and narcotics trace detection solutions for the homeland security market. Combining Syagen's technologies with Morpho's global commercial and service reach is expected to generate strong growth potential and offer enhanced explosives trace detection capability, especially against emerging nonconventional explosives threats.
"Syagen's unique mass spectrometry technology combined with Morpho's trace detection will help deliver the solutions customers need for detecting emerging, nonconventional explosives threats,” said Dennis Cooke, President and CEO, Morpho Detection. "We are pleased to welcome Syagen's superb team of mass spectrometry technical experts and their technology and entrepreneurial spirit to the Morpho team.”
“I am very proud of Syagen's accomplishments and the leading role we have played in the development of mass spectrometry technologies to meet some of our nation's most critical security needs," said Jack Syage, President and CEO of Syagen Technology. “We are excited to be part of Morpho and look forward to being part of an organization that has such strong global reach and extensive commercial experience to bring our technologies to the security and defense markets.”
Morpho expects to operate Syagen as a mass spectrometry technical center of excellence, developing its next generation of explosives and narcotics trace detection systems for its high-profile public, private and government customers around the world.
The boards of directors for Syagen and MDI have approved the transaction.